Alliancebernstein L.P. Sells 36,368 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Alliancebernstein L.P. lessened its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 29.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 88,246 shares of the company's stock after selling 36,368 shares during the period. Alliancebernstein L.P. owned approximately 0.14% of Kymera Therapeutics worth $3,550,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of KYMR. JPMorgan Chase & Co. grew its stake in shares of Kymera Therapeutics by 212.6% in the third quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company's stock worth $6,649,000 after purchasing an additional 95,547 shares in the last quarter. HighTower Advisors LLC bought a new position in Kymera Therapeutics in the 3rd quarter valued at about $494,000. Charles Schwab Investment Management Inc. increased its stake in Kymera Therapeutics by 5.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 387,187 shares of the company's stock valued at $15,577,000 after buying an additional 20,346 shares during the period. Victory Capital Management Inc. raised its position in shares of Kymera Therapeutics by 174.2% during the 4th quarter. Victory Capital Management Inc. now owns 19,899 shares of the company's stock worth $801,000 after buying an additional 12,643 shares in the last quarter. Finally, Schroder Investment Management Group lifted its stake in shares of Kymera Therapeutics by 14.1% in the 4th quarter. Schroder Investment Management Group now owns 163,896 shares of the company's stock worth $6,444,000 after acquiring an additional 20,204 shares during the period.

Kymera Therapeutics Stock Up 3.8 %

Shares of KYMR stock traded up $0.95 during trading hours on Friday, reaching $25.97. 468,785 shares of the stock traded hands, compared to its average volume of 549,679. The firm has a market capitalization of $1.69 billion, a PE ratio of -11.10 and a beta of 2.22. Kymera Therapeutics, Inc. has a 1-year low of $19.45 and a 1-year high of $53.27. The business has a fifty day moving average price of $30.47 and a 200 day moving average price of $39.00.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.12). The firm had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. Research analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Bruce N. Jacobs sold 7,035 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the transaction, the chief financial officer now directly owns 201,886 shares in the company, valued at $6,147,428.70. The trade was a 3.37 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Jeremy G. Chadwick sold 1,383 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $42,112.35. Following the transaction, the chief operating officer now directly owns 67,800 shares in the company, valued at approximately $2,064,510. The trade was a 2.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,659 shares of company stock valued at $324,567. Corporate insiders own 15.82% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Citigroup started coverage on shares of Kymera Therapeutics in a research note on Thursday, March 13th. They set a "buy" rating and a $52.00 price objective on the stock. Leerink Partners reiterated an "outperform" rating and set a $60.00 price target on shares of Kymera Therapeutics in a research report on Friday, December 27th. HC Wainwright upped their price objective on Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a report on Friday, February 28th. Finally, Stephens reaffirmed an "overweight" rating and set a $60.00 target price on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Three analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $56.36.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.